

Dong Hyun Sinn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5806282/publications.pdf>

Version: 2024-02-01

236
papers

5,765
citations

76326

40
h-index

128289

60
g-index

246
all docs

246
docs citations

246
times ranked

7207
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative gadoteric acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 526-534.	3.7	299
2	Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablation. <i>Annals of Surgery</i> , 2021, 273, 564-571.	4.2	184
3	Therapeutic Effect of Lactobacillus acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2714-2718.	2.3	152
4	Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. <i>Hepatology</i> , 2017, 66, 335-343.	7.3	144
5	Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. <i>Gut</i> , 2017, 66, 323-329.	12.1	125
6	Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. <i>Journal of Hepatology</i> , 2017, 67, 1274-1280.	3.7	120
7	Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. <i>Hepatology</i> , 2015, 62, 694-701.	7.3	106
8	Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes. <i>Journal of Hepatology</i> , 2018, 69, 70-78.	3.7	106
9	Ultrasonographically Detected Non-Alcoholic Fatty Liver Disease Is an Independent Predictor for Identifying Patients With Insulin Resistance in Non-Obese, Non-Diabetic Middle-Aged Asian Adults. <i>American Journal of Gastroenterology</i> , 2012, 107, 561-567.	0.4	104
10	Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. <i>Gastroenterology</i> , 2016, 151, 481-488.e1.	1.3	95
11	Efficacy and Tolerability of Split-Dose Magnesium Citrate: Low-Volume (2 Liters) Polyethylene Glycol vs. Single- or Split-Dose Polyethylene Glycol Bowel Preparation for Morning Colonoscopy. <i>American Journal of Gastroenterology</i> , 2010, 105, 1319-1326.	0.4	89
12	Deep learning with ultrasonography: automated classification of liver fibrosis using a deep convolutional neural network. <i>European Radiology</i> , 2020, 30, 1264-1273.	4.5	77
13	Bedside index for severity in acute pancreatitis: comparison with other scoring systems in predicting severity and organ failure. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2013, 12, 645-650.	1.3	76
14	Blood lead is significantly associated with metabolic syndrome in Korean adults: an analysis based on the Korea National Health and Nutrition Examination Survey (KNHANES), 2008. <i>Cardiovascular Diabetology</i> , 2013, 12, 9.	6.8	70
15	Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. <i>Scientific Reports</i> , 2018, 8, 4718.	3.3	68
16	Percutaneous US/MRI Fusion-guided Radiofrequency Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma: Technical Feasibility and Therapeutic Outcomes. <i>Radiology</i> , 2018, 288, 878-886.	7.3	68
17	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	8.2	68
18	A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2017, 52, 1201-1210.	5.1	67

#	ARTICLE	IF	CITATIONS
19	Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 2023-2032.	7.3	66
20	Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 833-839.	2.8	66
21	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 411-429.	8.9	66
22	Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. <i>Liver International</i> , 2018, 38, 1442-1448.	3.9	65
23	Laparoscopic Donor Hepatectomy for Adult Living Donor Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2018, 24, 1545-1553.	2.4	65
24	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019, 14, e0210730.	2.5	64
25	Effect of Balloon-Occluded Retrograde Transvenous Obliteration on the Natural History of Coexisting Esophageal Varices. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 974-979.	2.2	60
26	Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma – emphasis on association of local tumor progression and overall survival. <i>European Radiology</i> , 2020, 30, 2391-2400.	4.5	60
27	Mortality after surgery in patients with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 51-59.	1.6	58
28	Safety of the Use of Blood Salvage and Autotransfusion During Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2016, 264, 339-343.	4.2	57
29	Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 345-353.	3.7	54
30	The recommended treatment algorithms of the <sc>BCLC</sc> and <sc>HKLC</sc> staging systems: does following these always improve survival rates for <sc>HCC</sc> patients?. <i>Liver International</i> , 2016, 36, 1490-1497.	3.9	51
31	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. <i>Journal of Hepatology</i> , 2015, 62, 1112-1121.	3.7	50
32	Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, 1144-1152.	3.7	49
33	Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort. <i>PLoS ONE</i> , 2014, 9, e112184.	2.5	49
34	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	3.7	48
35	Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. <i>European Journal of Endocrinology</i> , 2019, 181, 185-192.	3.7	46
36	Characteristics and Discrepancies in Acute-on-Chronic Liver Failure: Need for a Unified Definition. <i>PLoS ONE</i> , 2016, 11, e0146745.	2.5	45

#	ARTICLE	IF	CITATIONS
37	Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1275-1281.	3.7	44
38	Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3235-3242.	2.3	44
39	Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread. <i>PLoS ONE</i> , 2015, 10, e0124434.	2.5	43
40	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	3.7	43
41	Increasing Incidence of Inflammatory Bowel Disease Among Young Men in Korea Between 2003 and 2008. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1154-1159.	2.3	42
42	Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. <i>Liver International</i> , 2018, 38, 68-75.	3.9	42
43	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 250-258.	8.9	42
44	Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 516-528.	8.9	42
45	Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1504-1509.	2.8	40
46	Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications. <i>European Radiology</i> , 2019, 29, 654-662.	4.5	38
47	Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 306-312.	2.8	37
48	Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	37
49	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1540-1550.	3.7	36
50	Disease progression and the risk factor analysis for chronic hepatitis C. <i>Liver International</i> , 2008, 28, 1363-1369.	3.9	35
51	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian Patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, no-no.	2.8	34
52	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 1407-1414.	4.0	33
53	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. <i>PLoS ONE</i> , 2016, 11, e0165722.	2.5	33
54	The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1465-1472.	2.0	31

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. <i>Liver Cancer</i> , 2021, 10, 52-62.	7.7	30
56	Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. <i>Liver International</i> , 2012, 32, 937-944.	3.9	29
57	Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2014, 234, 270-275.	0.8	29
58	Impact of previous gastric or colonic resection on polyethylene glycol bowel preparation for colonoscopy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 1554-1559.	2.4	28
59	A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2014, 46, 813-817.	0.9	28
60	Case-matched comparison of ABO-incompatible and ABO-compatible living donor liver transplantation. <i>British Journal of Surgery</i> , 2016, 103, 276-283.	0.3	28
61	Cell-surface major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in hepatocellular carcinomas. <i>Scientific Reports</i> , 2017, 7, 13201.	3.3	26
62	Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 896-903.	2.0	26
63	The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2021, 89, 48-55.	2.2	26
64	Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. <i>World Journal of Gastroenterology</i> , 2012, 18, 6996.	3.3	26
65	Pre-S Mutation Is a Significant Risk Factor for Hepatocellular Carcinoma Development: A Long-Term Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2013, 58, 751-758.	2.3	25
66	ABO-incompatible Living Donor Liver Transplantation With Rituximab and Total Plasma Exchange Does Not Increase Hepatocellular Carcinoma Recurrence. <i>Transplantation</i> , 2018, 102, 1695-1701.	1.0	25
67	Sarcopenia as a predictor of post-transplant tumor recurrence after living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria. <i>Scientific Reports</i> , 2018, 8, 7157.	3.3	25
68	Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. <i>Cancers</i> , 2020, 12, 2791.	3.7	25
69	Steatosis Among Living Liver Donors Without Evidence of Fatty Liver on Ultrasonography. <i>Transplantation</i> , 2013, 95, 1404-1409.	1.0	24
70	Early Enteral Feeding After Living Donor Liver Transplantation Prevents Infectious Complications. <i>Medicine (United States)</i> , 2015, 94, e1771.	1.0	24
71	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 47794-47807.	1.8	24
72	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. <i>BMC Cancer</i> , 2019, 19, 523.	2.6	24

#	ARTICLE	IF	CITATIONS
73	Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection. <i>Cancer Research and Treatment</i> , 2020, 52, 1145-1152.	3.0	24
74	Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study. <i>Hepatology</i> , 2022, 76, 1746-1754.	7.3	24
75	Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1100-1106.	2.8	23
76	Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1062-1071.	2.3	23
77	Validation of prognostic scores to predict short-term mortality in patients with acute-on-chronic liver failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 900-909.	2.8	23
78	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. <i>Gut and Liver</i> , 2017, 11, 528-534.	2.9	22
79	Efficacy of peginterferon-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 469-476.	2.8	21
80	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	3.9	21
81	Association between Serum Osteocalcin Levels and Non-Alcoholic Fatty Liver Disease in Women. <i>Digestion</i> , 2015, 91, 150-157.	2.3	21
82	Current status and strategies for viral hepatitis control in Korea. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 189-195.	8.9	21
83	Long-term Prognosis of Acute-on-Chronic Liver Failure Survivors. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 134-141.	2.2	21
84	Current status and strategies for the control of viral hepatitis A in Korea. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 196-204.	8.9	21
85	Appropriate empirical antibiotic use and 30-d mortality in cirrhotic patients with bacteremia. <i>World Journal of Gastroenterology</i> , 2015, 21, 3587.	3.3	21
86	Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy. <i>JHEP Reports</i> , 2020, 2, 100175.	4.9	20
87	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	12.1	20
88	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. <i>Annals of Surgical Treatment and Research</i> , 2020, 99, 238.	1.0	20
89	The Speed of Eating and Functional Dyspepsia in Young Women. <i>Gut and Liver</i> , 2010, 4, 173-178.	2.9	20
90	Predicting Hepatic Steatosis in Living Liver Donors via Noninvasive Methods. <i>Medicine (United States)</i> , 2016, 95, e2718.	1.0	19

#	ARTICLE	IF	CITATIONS
91	Association between cancer stigma and job loss among cancer survivors. <i>Psycho-Oncology</i> , 2021, 30, 1347-1355.	2.3	19
92	Incidental Microscopic Bile Duct Tumor Thrombi in Hepatocellular Carcinoma after Curative Hepatectomy. <i>Medicine (United States)</i> , 2015, 94, e450.	1.0	18
93	Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. <i>Journal of Viral Hepatitis</i> , 2015, 22, 539-550.	2.0	18
94	Tumefactive Gallbladder Sludge at US: Prevalence and Clinical Importance. <i>Radiology</i> , 2017, 283, 570-579.	7.3	18
95	Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. <i>Annals of Surgery</i> , 2018, 268, 1043-1050.	4.2	18
96	RF Ablation Versus Cryoablation for Small Perivascular Hepatocellular Carcinoma: Propensity Score Analyses of Mid-Term Outcomes. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 434-444.	2.0	18
97	Clinical usefulness of glycosylated hemoglobin as a predictor of adenomatous polyps in the colorectum of middle-aged males. <i>Cancer Causes and Control</i> , 2010, 21, 939-944.	1.8	17
98	Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 636-646.	1.7	17
99	Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2028-2035.	2.8	17
100	Radiofrequency ablation for subcardiac hepatocellular carcinoma: therapeutic outcomes and risk factors for technical failure. <i>European Radiology</i> , 2019, 29, 2706-2715.	4.5	17
101	A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. <i>BMC Cancer</i> , 2020, 20, 504.	2.6	17
102	Assessment of scoring systems for acute-on-chronic liver failure at predicting short-term mortality in patients with alcoholic hepatitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 9205.	3.3	17
103	Regional differences of the effects of acetylcholine in the human gastric circular muscle. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G1198-G1203.	3.4	16
104	Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2018, 36, 25-34.	1.5	16
105	Factors associated with adherence to the recommended postpolypectomy surveillance interval. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 1690-1695.	2.4	15
106	Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2016, 10, 939-947.	2.9	15
107	Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 3785.	3.3	15
108	Child-Pugh, MELD, MELD-Na, and ALBI scores: which liver function models best predicts prognosis for HCC patient with ascites?. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 951-957.	1.5	15

#	ARTICLE	IF	CITATIONS
109	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	4.2	15
110	Efficacy and Safety of an mHealth App and Wearable Device in Physical Performance for Patients With Hepatocellular Carcinoma: Development and Usability Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14435.	3.7	15
111	The Korean guideline for hepatocellular carcinoma surveillance. <i>Journal of the Korean Medical Association</i> , 2015, 58, 385.	0.3	14
112	Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. <i>International Journal of Epidemiology</i> , 2020, 49, 1562-1571.	1.9	14
113	Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e529-e534.	1.6	14
114	Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. <i>Digestive and Liver Disease</i> , 2021, 53, 1004-1010.	0.9	14
115	Metabolically-healthy obesity is associated with higher prevalence of colorectal adenoma. <i>PLoS ONE</i> , 2017, 12, e0179480.	2.5	14
116	A case of ruptured hepatic angiomyolipoma in a young male. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 179-183.	8.9	14
117	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2016, 10, 295.	2.9	14
118	Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. <i>Gut and Liver</i> , 2016, 10, 796-802.	2.9	14
119	Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 329-335.	0.4	14
120	Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 519-528.	3.7	14
121	Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: A prospective, randomized trial. <i>Pancreatology</i> , 2014, 14, 263-267.	1.1	13
122	Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3354-3362.	2.3	13
123	Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1447-1452.	1.6	13
124	Nomograms in Hepatectomy Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1559-1567.	1.7	13
125	Vanishing washout of hepatocellular carcinoma according to the presence of hepatic steatosis: diagnostic performance of CT and MRI. <i>European Radiology</i> , 2021, 31, 3315-3325.	4.5	13
126	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1392-1399.	2.0	13

#	ARTICLE	IF	CITATIONS
127	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 42-50.	8.9	13
128	Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. <i>Scientific Reports</i> , 2022, 12, 7647.	3.3	13
129	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. <i>Journal of Korean Medical Science</i> , 2015, 30, 1618.	2.5	12
130	Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: A randomized prospective study. <i>Liver Transplantation</i> , 2016, 22, 209-216.	2.4	12
131	Non-alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1053-1058.	2.8	12
132	Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images. <i>Korean Journal of Radiology</i> , 2019, 20, 236.	3.4	12
133	Use of Gadoxetic Acid-enhanced Liver MRI and Mortality in More than 30,000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis. <i>Radiology</i> , 2020, 295, 114-124.	7.3	12
134	Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial. <i>Oncotarget</i> , 2017, 8, 52651-52664.	1.8	12
135	Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naïve hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 1328-1336.	4.2	12
136	Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1215-1222.	5.0	12
137	Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. <i>Hepatology International</i> , 2013, 7, 1010-1018.	4.2	11
138	Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. <i>Clinical Radiology</i> , 2017, 72, 141-149.	1.1	11
139	Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. <i>Cancers</i> , 2019, 11, 1295.	3.7	11
140	Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. <i>BMC Cancer</i> , 2019, 19, 286.	2.6	11
141	Deep learning-based automated quantification of the hepatorenal index for evaluation of fatty liver by ultrasonography. <i>Ultrasonography</i> , 2021, 40, 565-574.	2.3	11
142	Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 65-78.	1.7	11
143	Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4565-4573.	2.3	11
144	Methylation and API2/MALT1 fusion in colorectal extranodal marginal zone lymphoma. <i>Modern Pathology</i> , 2009, 22, 314-320.	5.5	10

#	ARTICLE	IF	CITATIONS
145	Pure red-cell aplasia and autoimmune hemolytic anemia in a patient with acute hepatitis A. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 204.	8.9	10
146	Longitudinal change of liver stiffness by transient elastography in chronic hepatitis B patients treated with nucleos(t)ide analogue. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 195-200.	1.5	10
147	Comparison of Super-Resolution US and Contrast Material-enhanced US in Detection of the Spoke Wheel Sign in Patients with Focal Nodular Hyperplasia. <i>Radiology</i> , 2021, 298, 82-90.	7.3	10
148	The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nationwide Cohort Study. <i>Hepatology</i> , 2021, 74, 2988-2997.	7.3	10
149	Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 173.	8.9	9
150	Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. <i>Abdominal Radiology</i> , 2018, 43, 2309-2320.	2.1	9
151	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	4.4	9
152	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	2.5	9
153	Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. <i>PLoS ONE</i> , 2015, 10, e0123554.	2.5	9
154	Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 380-395.	8.9	9
155	Higher Bilirubin Levels of Healthy Living Liver Donors Are Associated With Lower Posttransplant Hepatocellular Carcinoma Recurrence. <i>Transplantation</i> , 2016, 100, 1933-1938.	1.0	8
156	Prognosis of preoperative positron emission tomography uptake in hepatectomy patients. <i>Annals of Surgical Treatment and Research</i> , 2018, 94, 183.	1.0	8
157	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. <i>Cancers</i> , 2019, 11, 1721.	3.7	8
158	Mean and visit-to-visit variability of glycated hemoglobin, and the risk of nonalcoholic fatty liver disease. <i>Journal of Diabetes Investigation</i> , 2020, 12, 1252-1262.	2.4	8
159	Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. <i>Journal of Viral Hepatitis</i> , 2020, 27, 739-746.	2.0	8
160	Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 315-324.	2.3	8
161	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567.	3.7	8
162	Change in cross-sectional area of esophageal muscle does not correlate with the outcome of achalasia after pneumatic balloon dilatation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 539-543.	2.8	7

#	ARTICLE	IF	CITATIONS
163	Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 957-963.	2.8	7
164	Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria. <i>Medicine (United States)</i> , 2016, 95, e4735.	1.0	7
165	Incidence of and Risk Factors for Alcohol Relapse After Liver Transplantation for Alcoholic Liver Disease: Comparison Between Deceased Donor and Living Donor Liver Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 672-680.	1.7	7
166	Evaluating mortality and recovery of extreme hyperbilirubinemia in critically ill patients by phasing the peak bilirubin level: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0255230.	2.5	7
167	Initial experience with high-volume plasma exchange in patients with acute liver failure. <i>Journal of Clinical Apheresis</i> , 2021, 36, 379-389.	1.3	7
168	Cause of Mortality for Hepatocellular Carcinoma Patients who were Diagnosed within the Milan Criteria. <i>Journal of Liver Cancer</i> , 2016, 16, 101-107.	1.1	7
169	Effect of Perfluorobutane Microbubbles on Radiofrequency Ablation for Hepatocellular Carcinoma: Suppression of Steam Popping and Its Clinical Implication. <i>Korean Journal of Radiology</i> , 2020, 21, 1077.	3.4	7
170	Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 232.	8.9	7
171	The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study. <i>Gut and Liver</i> , 2012, 6, 241-248.	2.9	7
172	Laparoscopic Hepatic Resection Versus Laparoscopic Radiofrequency Ablation for Subcapsular Hepatocellular Carcinomas Smaller Than 3 cm: Analysis of Treatment Outcomes Using Propensity Score Matching. <i>Korean Journal of Radiology</i> , 2022, 23, 615.	3.4	7
173	Are the Echogenicities on Intraductal Ultrasonography Really Biliary Microlithiasis?. <i>Digestive Diseases and Sciences</i> , 2010, 55, 836-841.	2.3	6
174	Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis. <i>Medicine (United States)</i> , 2016, 95, e2578.	1.0	6
175	Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial. <i>International Journal of Hyperthermia</i> , 2016, 32, 331-338.	2.5	6
176	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	2.2	6
177	Virological response to adefovir monotherapy and the risk of adefovir resistance. <i>World Journal of Gastroenterology</i> , 2011, 17, 3526.	3.3	6
178	Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study. <i>BMC Medicine</i> , 2022, 20, 18.	5.5	6
179	Adenoma incidence after resection of sporadic colorectal cancer with microsatellite instability. <i>Journal of Surgical Oncology</i> , 2010, 101, 577-581.	1.7	5
180	Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine resistance. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1454-1460.	2.8	5

#	ARTICLE	IF	CITATIONS
181	Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. Scandinavian Journal of Gastroenterology, 2018, 53, 727-733.	1.5	5
182	Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. Digestive Diseases and Sciences, 2021, 66, 2816-2825.	2.3	5
183	Gadoxetic acid-enhanced MRI for differentiating hepatic sclerosing hemangioma from malignant tumor. European Journal of Radiology, 2021, 135, 109474.	2.6	5
184	Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. PLoS ONE, 2015, 10, e0144777.	2.5	5
185	A Survey of Liver Cancer Specialists's Views on the National Liver Cancer Screening Program in Korea. Journal of Liver Cancer, 2020, 20, 53-59.	1.1	5
186	Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. European Journal of Gastroenterology and Hepatology, 2022, 34, 69-75.	1.6	5
187	Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. Korean Journal of Internal Medicine, 2022, 37, 1082-1087.	1.7	5
188	Defining Virologic Relapse in Chronic Hepatitis B. Digestive Diseases and Sciences, 2011, 56, 2432-2438.	2.3	4
189	Gadoxetic acid-enhanced magnetic resonance imaging characteristics of hepatocellular carcinoma occurring in liver transplants. European Radiology, 2017, 27, 3117-3127.	4.5	4
190	Development of Barrett's Esophagus Soon after Total Gastrectomy. Gut and Liver, 2008, 2, 51-53.	2.9	4
191	Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience. Annals of Surgical Treatment and Research, 2018, 95, 147.	1.0	3
192	Weight Change and Development of Subclinical Carotid Atherosclerosis Among Metabolically Healthy Adults: A Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e410-e416.	3.6	3
193	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. Digestive Diseases and Sciences, 2020, 66, 2427-2438.	2.3	3
194	Comparison of ICC patients with hepatitis B infection to those with no major risk factors for HCC. Hpb, 2021, 23, 945-953.	0.3	3
195	Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels. World Journal of Gastroenterology, 2013, 19, 2256.	3.3	3
196	Hepatogastroenterology. Hepato-Gastroenterology, 2012, 59, 1-6.	0.5	3
197	Anti-fibrotic effect of bovine colostrum in carbon tetrachloride-induced hepatic fibrosis. Precision and Future Medicine, 2017, 1, 88-94.	1.6	3
198	Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scandinavian Journal of Gastroenterology, 2021, , 1-8.	1.5	3

#	ARTICLE	IF	CITATIONS
199	Formal documentation of withdrawal time improves the quality of colonoscopic observation. <i>Hepato-Gastroenterology</i> , 2011, 58, 779-84.	0.5	3
200	Screening for extrahepatic metastases by additional staging modalities is required for hepatocellular carcinoma patients beyond modified UICC stage T1. <i>Hepato-Gastroenterology</i> , 2013, 60, 328-32.	0.5	3
201	Portal Vein Stenting for Portal Biliopathy with Jaundice. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 620-623.	2.0	2
202	Differences in Peripheral Blood Lymphocytes between Brand-Name and Generic Tacrolimus Used in Stable Liver Transplant Recipients. <i>Medical Principles and Practice</i> , 2017, 26, 221-228.	2.4	2
203	The Impact of Previous Acute Decompensation on the Long-Term Prognosis of Alcoholic Hepatitis in Cirrhotic Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1600.	2.4	2
204	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2021, 53, 210-215.	0.9	2
205	Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea. <i>Korean Journal of Transplantation</i> , 2021, 35, 24-32.	0.1	2
206	Vaccination Rate and Seroepidemiology of Hepatitis A in Chronic-Hepatitis-B-Infected Individuals in the Korean Army. <i>Gut and Liver</i> , 2010, 4, 207-211.	2.9	2
207	Screening for Extrahepatic Metastases by Additional Staging Modalities is Required for Hepatocellular Carcinoma Patients Beyond Modified UICC Stage T1. <i>Hepato-Gastroenterology</i> , 2012, , .	0.5	2
208	Prevalence, risk factors, and short-term outcomes of postparacentesis acute kidney injury using revised criteria of the international club of ascites. <i>Medicine (United States)</i> , 2021, 100, e27431.	1.0	2
209	Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging. <i>Ultrasonography</i> , 2022, 41, 519-529.	2.3	2
210	Effectiveness of each Bethesda marker in defining microsatellite instability when screening for Lynch syndrome. <i>Hepato-Gastroenterology</i> , 2009, 56, 672-6.	0.5	2
211	Serum alpha-fetoprotein may have a significant role in the surveillance of hepatocellular carcinoma in hepatitis B endemic areas. <i>Hepato-Gastroenterology</i> , 2015, 62, 327-32.	0.5	2
212	Pathological bolus exposure may define gastro-esophageal reflux better than pathological acid exposure in patients with globus. <i>Hepato-Gastroenterology</i> , 2012, 59, 317-20.	0.5	2
213	Pre-transplant Predictors for 3-Month Mortality after Living Donor Liver Transplantation. <i>The Journal of the Korean Society for Transplantation</i> , 2014, 28, 226.	0.2	1
214	Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3794-3800.	2.3	1
215	The Author's Response: Anti-Viral Therapy for Compensated Liver Cirrhosis Patients with Normal Alanine Aminotransferase. <i>Journal of Korean Medical Science</i> , 2016, 31, 825.	2.5	1
216	The qualitative and quantitative image analysis of MR imaging in patients with acute-on-chronic liver failure. <i>Clinical Imaging</i> , 2018, 47, 18-24.	1.5	1

#	ARTICLE	IF	CITATIONS
217	FRI-492-Long-term outcome according to initial treatment modality in multiple hepatocellular carcinoma within the Milan criteria. <i>Journal of Hepatology</i> , 2019, 70, e615.	3.7	1
218	Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. <i>PLoS ONE</i> , 2021, 16, e0255624.	2.5	1
219	Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 315-317.	8.9	1
220	Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 194-204.	1.7	1
221	Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment. <i>PLoS ONE</i> , 2022, 17, e0262750.	2.5	1
222	Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2022, 151, 110328.	2.6	1
223	Documentation of Withdrawal Time Improves Adenoma Detection During Colonoscopy. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB297.	1.0	0
224	Letter: <i>Helicobacter pylori</i> -related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 577-578.	3.7	0
225	FRI-479-Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. <i>Journal of Hepatology</i> , 2019, 70, e609.	3.7	0
226	Reply. <i>Hepatology</i> , 2020, 71, 2174-2175.	7.3	0
227	Estimation of hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2020, 73, S399.	3.7	0
228	Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2020, 52, 881-888.	0.6	0
229	REPLY:. <i>Hepatology</i> , 2021, 73, 1622-1623.	7.3	0
230	Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 274-280.	1.5	0
231	Reply to "Emergent liver transplantation for patients with acute-on-chronic liver failure". <i>Digestive and Liver Disease</i> , 2021, 53, 1361.	0.9	0
232	Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 151.	8.9	0
233	Comparison of Mac-2 Binding Protein Glycosylation Isomer, Fibroscan, and Other Fibrosis Markers for Assessing Liver Cirrhosis in Patients with Chronic Hepatitis B Virus-mediated Hepatocellular Carcinoma. <i>Laboratory Medicine Online</i> , 2020, 10, 109.	0.2	0
234	Comparative evaluation of QuantiFERON-TB Gold Plus for diagnosis of latent tuberculosis infection during solid organ transplantation. <i>Korean Journal of Transplantation</i> , 2020, 34, 8-14.	0.1	0

#	ARTICLE	IF	CITATIONS
235	Treatment of choice for advanced HCC with small future remnant liver volume for a hepatologist?. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S15-S15.	0.1	0
236	Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. Scandinavian Journal of Gastroenterology, 0, , 1-8.	1.5	0